# Acacia Pharma Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acacia-pharma-group

- Industry: Pharmaceuticals
- Headquarters: UK
- Website: www.acaciapharma.com
- Total disclosed funding: $34M
- Latest round: Series B (Sep 3, 2013)
- Investors on record: 4

## About

Acacia Pharma Group Plc is a biopharmaceutical company focused on developing and commercializing hospital products, particularly in anesthesia and surgery, to enhance patient care.Acacia Pharma Group Plc, founded in 2015 in the UK, specializes in hospital products for anesthesia and surgical teams. The company has completed a total of 8 deals, with its most recent being a Trade Sale in which Eagle Pharmaceuticals, Inc. acquired Acacia for EUR 94.7 mn on August 13, 2020. The company's headquarters is located in the UK, and it was formed to specifically address needs in the medical field. Its founder has not been specifically identified.Acacia Pharma Group Plc specializes in the development and commercialization of differentiated hospital products designed primarily for anesthesia and surgical teams. The company’s portfolio includes products such as Barhemsys® for managing postoperative nausea and vomiting and Byfavo®, an anesthetic agent that provides rapid onset and recovery. These products are marketed directly to healthcare providers and institutions across the United States, including hospitals and surgical centers, focusing on innovative medical solutions to improve patient outcomes.Acacia Pharma generated revenue of EUR 1,163,000 in 2021. The company operates a B2B model, selling its pharmaceutical products directly to healthcare providers, primarily hospitals and surgical facilities, which negotiate pricing agreements based on clinical value and need. Acacia Pharma's partnerships with oncology and surgical teams enhance its market reach and facilitate the adoption of its therapies.Acacia Pharma Group Plc aims to expand its product portfolio by developing new products targeting unmet medical needs in anesthesia and surgery, with potential launches planned for the upcoming years. The company is also looking to penetrate new markets, particularly in Europe and the Asia-Pacific region, by 2023. The recent funding from the EUR 94.7 mn Trade Sale will be utilized to support these growth initiatives, including research and development for new product launches and market expansion efforts.

## Funding rounds

- Series B, Sep 3, 2013, $24M — Gilde Healthcare, F-Prime Capital, Lundbeckfond Ventures, Novo Holdings
- Series A, Mar 31, 2011, $10M — Gilde Healthcare, Lundbeckfond Ventures

## Investors

- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series B
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B
- Novo Holdings — Series B